PTC Therapeutics, Inc.
vatiquinone
Friedreich’s ataxia
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on vatiquinone for Friedreich’s ataxia is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Primary endpoint will be change in mFARS from baseline to 24 months”